Sponsor Pipeline

Shenzhen Geno-Immune Medical Institute Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
18
Active Trials
16
Recruiting
10
Disease Areas
Active Trials by Phase
Phase 1/2
11
Phase 1
6
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07477600 cfMSC Stem Cell Therapy Targeting COPD Chronic Obstructive Pulmonary Disease (COPD) Recruiting
NCT07495956 cfMSC Therapy for Diabetes Type II Diabetes Mellitus Recruiting
NCT07501156 H3K27M-specific Immune Effector Cells Targeting DMG/DIPG Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma Recruiting
NCT04016129 CAR-T Immunotherapy Targeting CD19- ALL B-cell Leukemia Recruiting
NCT03222674 Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Acute Myeloid Leukemia Recruiting
NCT03535246 Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells Cancer Recruiting
NCT03614650 Immunotherapy Treating GI Cancer Cancer Recruiting
NCT04010877 Multiple CAR-T Cell Therapy Targeting AML Acute Myeloid Leukemia Recruiting
NCT06429150 Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma Multiple Myeloma Recruiting
NCT06435897 Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells Autoimmune Diseases Recruiting
NCT03393962 Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors Ovarian Cancer Enrolling by Invitation
Phase 1
NCT03217032 Lentiviral FVIII Gene Therapy Hemophilia A Recruiting
NCT03961243 Lentiviral FIX Gene Therapy Hemophilia B Recruiting
NCT05995028 Universal 4SCAR7U Targeting CD7-positive Malignancies T-cell Acute Lymphoblastic Leukemia Recruiting
NCT06006741 Universal CAR-T Cells Targeting Multiple Myeloma Multiple Myeloma in Remission Recruiting
NCT06435910 Engineered Dendritic Cell Vaccines for Multiple Myeloma Multiple Myeloma or Plasmacytoma Recruiting
NCT03170141 Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme Glioblastoma Multiforme of Brain Enrolling by Invitation
Not specified
NCT03645486 Lentiviral Gene Therapy for CGD Chronic Granulomatous Disease Recruiting
Disease Areas
Get alerts when Shenzhen Geno-Immune Medical Institute's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free